The RECAP Test Rapidly and Reliably Identifies Homologous Recombination-Deficient Ovarian Carcinomas

Simple Summary The sensitivity to PARP inhibitors (PARPi) is related to tumor-specific defects in homologous recombination (HR) and extends beyond BRCA1/2-related deficiencies. A robust method to identify HR-deficient (HRD) carcinomas is therefore of utmost clinical importance. In this study, we evaluated the use of a functional test (the RECAP test) for the identification of HRD ovarian carcinomas. Forty-nine epithelial ovarian carcinomas (EOC) were analyzed by the RECAP test. Thirty-nine of these tumors were of the high-grade serous (HGSOC) histologic subtype. Ten out of these 39 HGSOC specimens showed HRD (26%), whereas ovarian carcinomas of other histologic subtypes (n = 10) were all HR-proficient (HRP). Eight out of 9 sequenced HRD tumors showed pathogenic BRCA1/2 variants or BRCA1 promoter hypermethylation. This study shows that the RECAP test is a reliable and rapid test to identify functional deficiencies in HR and a good alternative to DNA-based HRD tests. Abstract Recent studies have shown that the efficacy of PARP inhibitors in epithelial ovarian carcinoma (EOC) is related to tumor-specific defects in homologous recombination (HR) and extends beyond BRCA1/2 deficient EOC. A robust method with which to identify HR-deficient (HRD) carcinomas is therefore of utmost clinical importance. In this study, we investigated the proficiency of a functional HR assay based on the detection of RAD51 foci, the REcombination CAPacity (RECAP) test, in identifying HRD tumors in a cohort of prospectively collected epithelial ovarian carcinomas (EOCs). Of the 39 high-grade serous ovarian carcinomas (HGSOC), the RECAP test detected 26% (10/39) to be HRD, whereas ovarian carcinomas of other histologic subtypes (n = 10) were all HR-proficient (HRP). Of the HRD tumors that could be sequenced, 8/9 showed pathogenic BRCA1/2 variants or BRCA1 promoter hypermethylation, indicating that the RECAP test reliably identifies HRD, including but not limited to tumors related to BRCA1/2 deficiency. Furthermore, we found a trend towards better overall survival (OS) of HGSOC patients with RECAP-identified HRD tumors compared to patients with HRP tumors. This study shows that the RECAP test is an attractive alternative to DNA-based HRD tests, and further development of a clinical grade RECAP test is clearly warranted.

[1]  F. Marmé,et al.  Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. , 2019, The New England journal of medicine.

[2]  B. Monk,et al.  Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. , 2019, The New England journal of medicine.

[3]  M. Morgan,et al.  Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. , 2019, The New England journal of medicine.

[4]  Lauren L. Ritterhouse,et al.  Germline BRCA-Associated Endometrial Carcinoma Is a Distinct Clinicopathologic Entity , 2019, Clinical Cancer Research.

[5]  L. Saal,et al.  Whole-genome-sequencing of triple negative breast cancers in a population-based clinical study , 2019, Nature Medicine.

[6]  J. Ledermann,et al.  ESGO consensus conference recommendations on ovarian cancer : pathology and molecular biology , early and advanced stages , borderline tumours and recurrent disease , 2019 .

[7]  A. Jager,et al.  Direct Ex Vivo Observation of Homologous Recombination Defect Reversal After DNA-Damaging Chemotherapy in Patients With Metastatic Breast Cancer. , 2019, JCO precision oncology.

[8]  A. Oza,et al.  Epithelial ovarian cancer , 2019, The Lancet.

[9]  D. G. Evans,et al.  Epithelial ovarian cancer risk: A review of the current genetic landscape , 2019, Clinical genetics.

[10]  B. Job,et al.  Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas , 2018, Clinical Cancer Research.

[11]  C. Caldas,et al.  A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation , 2018, EMBO molecular medicine.

[12]  Gabe S. Sonke,et al.  Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer , 2018, The New England journal of medicine.

[13]  D. Matei,et al.  Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy , 2018, British Journal of Cancer.

[14]  Sarah Keegan,et al.  Spatiotemporal dynamics of homologous recombination repair at single collapsed replication forks , 2018, Nature Communications.

[15]  C. V. van Asperen,et al.  Validation and Implementation of BRCA1/2 Variant Screening in Ovarian Tumor Tissue. , 2018, The Journal of molecular diagnostics : JMD.

[16]  A. Sieuwerts,et al.  Functional Ex Vivo Assay Reveals Homologous Recombination Deficiency in Breast Cancer Beyond BRCA Gene Defects , 2018, Clinical Cancer Research.

[17]  L. Kauppi,et al.  A Functional Homologous Recombination Assay Predicts Primary Chemotherapy Response and Long-Term Survival in Ovarian Cancer Patients , 2018, Clinical Cancer Research.

[18]  A. Jemal,et al.  Ovarian cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.

[19]  P. Kristel,et al.  RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  James X. Sun,et al.  Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial , 2017, The Lancet.

[21]  Val Gebski,et al.  Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. , 2017, The Lancet. Oncology.

[22]  E. Birney,et al.  HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures , 2017, Nature Medicine.

[23]  Kenneth D. Doig,et al.  Reversion of BRCA1/2 Germline Mutations Detected in Circulating Tumor DNA From Patients With High-Grade Serous Ovarian Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Ignace Vergote,et al.  Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. , 2016, The New England journal of medicine.

[25]  Yu Zhang,et al.  TP53 mutations in epithelial ovarian cancer. , 2016, Translational cancer research.

[26]  Erich P Huang,et al.  RECIST 1.1-Update and clarification: From the RECIST committee. , 2016, European journal of cancer.

[27]  G. Shapiro,et al.  Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer. , 2015, Cancer discovery.

[28]  B. Gilks,et al.  Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes , 2015, British Journal of Cancer.

[29]  Joshy George,et al.  Whole–genome characterization of chemoresistant ovarian cancer , 2015, Nature.

[30]  Nicolai J. Birkbak,et al.  Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs , 2015, Biomarker Research.

[31]  Alexander Gutin,et al.  Association of BRCA1/2defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes , 2014, Breast Cancer Research.

[32]  E. Yang,et al.  An ex vivo assay of XRT-induced Rad51 foci formation predicts response to PARP-inhibition in ovarian cancer. , 2014, Gynecologic oncology.

[33]  R. Zeillinger,et al.  BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients--a study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD). , 2014, European journal of cancer.

[34]  Jianping Lu,et al.  Correlation between gene expression and mutator phenotype predicts homologous recombination deficiency and outcome in ovarian cancer , 2014, Journal of Molecular Medicine.

[35]  A. Sieuwerts,et al.  Functional Ex Vivo Assay to Select Homologous Recombination–Deficient Breast Tumors for PARP Inhibitor Treatment , 2014, Clinical Cancer Research.

[36]  N. Curtin,et al.  Assessing the function of homologous recombination DNA repair in malignant pleural effusion (MPE) samples , 2014, British Journal of Cancer.

[37]  Benjamin J. Raphael,et al.  Integrated Analysis of Germline and Somatic Variants in Ovarian Cancer , 2014, Nature Communications.

[38]  Jaime Prat,et al.  Staging classification for cancer of the ovary, fallopian tube, and peritoneum , 2014, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[39]  Zoltan Szallasi,et al.  Tumor Mutation Burden Forecasts Outcome in Ovarian Cancer with BRCA1 or BRCA2 Mutations , 2013, PloS one.

[40]  P. Maxwell,et al.  Clinicopathological features of homologous recombination-deficient epithelial ovarian cancers: sensitivity to PARP inhibitors, platinum, and survival. , 2012, Cancer research.

[41]  A. Vincent-Salomon,et al.  Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. , 2012, Cancer research.

[42]  G. Mills,et al.  Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer , 2012, British Journal of Cancer.

[43]  The Cancer Genome Atlas Research Network.  Erratum: Integrated genomic analyses of ovarian carcinoma , 2012, Nature.

[44]  D. Matei,et al.  Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. , 2012, The New England journal of medicine.

[45]  Rochelle L. Garcia,et al.  Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing , 2011, Proceedings of the National Academy of Sciences.

[46]  Rochelle L. Garcia,et al.  Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[48]  Corneel Coens,et al.  Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial , 2010, The Lancet.

[49]  A. Ashworth,et al.  A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer , 2010, Clinical Cancer Research.

[50]  Y. Drew,et al.  Development of a Functional Assay for Homologous Recombination Status in Primary Cultures of Epithelial Ovarian Tumor and Correlation with Sensitivity to Poly(ADP-Ribose) Polymerase Inhibitors , 2010, Clinical Cancer Research.

[51]  D. Sgroi,et al.  Utility of DNA Repair Protein Foci for the Detection of Putative BRCA1 Pathway Defects in Breast Cancer Biopsies , 2009, Molecular Cancer Research.

[52]  A. Spurdle,et al.  Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results , 2008, Human mutation.

[53]  F. Couch,et al.  Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers , 2008, Nature.

[54]  Anne Floquet,et al.  Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. , 2017, The Lancet. Oncology.